Inozyme Pharma Inc (INZY) - News Archive

: Inozyme Pharma, a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases involving pathological mineralization, recently made significant strides in its clinical trials for I...

Inozyme Pharma, Inc. has recently made waves in the biopharmaceutical landscape with the announcement of promising preclinical data supporting its investigational therapy, INZ-701. Designed to address a spectrum of seri...

Inozyme Pharma Advances in Therapeutic Innovation: FDA Grants Fast Track Designation for INZ-701 in ABCC6 Deficiency Boston, MA In a significant stride towards addressing a critical medical need, Inozyme Pharma announce...

Inozyme Pharma, a clinical-stage biopharmaceutical company focused on rare diseases, recently announced the presentation of top-line data from its ongoing Phase 1/2 trials of INZ-701. The trials aim to evaluate the safe...

Inozyme Pharma Inc. recently announced that they have granted stock options to a new employee as an inducement to join the company. This news has sparked interest among shareholders and potential investors as they evalu...

is thrilled to present groundbreaking findings from Inozyme Pharma s ongoing Phase 1/2 trials of their innovative drug, INZ-701, targeting ABCC6 Deficiency (also known as PXE) and ENPP1 Deficiency. This article aims to...

Inozyme Pharma, a clinical-stage rare disease biopharmaceutical company, recently announced the granting of stock options to three new employees as part of its ongoing efforts to develop novel therapeutics for pathologi...

:This article discusses the latest developments in the treatment of ABCC6 and ENPP1 deficiencies through the ongoing Phase 1/2 trials of INZ-701 by Inozyme Pharma. These rare genetic conditions result in mineralization...

Inozyme Pharma Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company focusing on innovative therapeutics for pathologic mineralization and intimal proliferation, recently announced the granting of...